菟丝子多糖—羟基磷灰石复合物治疗松质骨骨缺损的实验研究
|
摘要
目的：观察菟丝子多糖—羟基磷灰石复合物局部植入对兔股骨髁部松质骨缺损模型的修复作用。
方法：将48只日本大耳白兔双侧股骨髁部进行松质骨缺损造模,造成股骨髁部直径6mm,深10mm的模型后,随机分为3组(实验组／对照组／模型组)：实验组缺损区局部植入菟丝子多糖-HA复合物；对照组缺损区局部植入BMP-HA-明胶复合物；模型组缺损区局部不植入药物。术后8、12周X摄片影像学评分后,取双侧股骨髁部松质骨骨缺损标本行大体观察、组织学观察并且对骨缺损修复面积和骨缺损修复率进行统计,比较3组之间差异。
结果：
术后影像学评分：8周时术后影像学评分为实验组3.071±0.475,对照组3.143±0.363,模型组1.167±0.389,实验组与对照组比较P>0.05,与模型组比较P<0.01；12周实验组3.571±0.514,对照组3.714±0.469,模型组1.833±0.835,实验组与对照组比较P>0.05,与模型组比较P<0.01。
大体观察：8周时,实验组缺损区周围肌肉等软组织轻微肿胀,颜色稍白,无充血水肿,缺损区植入物质地明显变软,明显吸收,股骨髁部骨缺损处有大量新生骨痂由周围向中心生长,骨缺损处新生骨痂与植入物边界模糊；对照组缺损区周围肌肉等软组织情况同实验组,可见植入物少量吸收,但硬度较实验组高,且缺损边缘新生骨痂量少于实验组；模型组缺损区周围肌肉等软组织轻微肿胀,骨缺损处有红色软组织充填,未见明显骨痂生长。12周时,实验组缺损区周围肌肉等软组织肿胀消退,颜色恢复正常,可见缺损区大量骨痂生成并充填,颜色较正常骨组织浅,硬度不及正常骨；对照组缺损区周围肌肉等软组织情况同上,但骨痂量较实验组少；模型组缺损区周围肌肉等软组织无肿胀,无渗出,周围有少量骨痂长出,但已硬化,较大缺损区内白色软组织充填于其中,骨痂与缺损区内软组织边界清楚。
骨缺损修复面积：8周时骨缺损修复面积为实验组21.558±0.933,对照组21.749±0.992,模型组17.003±1.423。实验组、对照组与模型组比较有极显著性差异(P<0.01),实验组与对照组比较无显著性差异(P>0.05)；12周实验组25.654±0.662,对照组25.734±0.681,模型组20.543±0.798。实验组与对照组比较无显著性差异(P>0.05),与模型组比较有极显著性差异(P<0.01)。
骨缺损修复率：8周时骨缺损修复率为实验组76.283±3.301,对照组76.961±3.509,模型组60.167±5.035。实验组与对照组比较无显著性差异(P>0.05),与模型组比较有极显著性差异(P<0.01)；12周时,实验组90.777±2.341,对照组91.062±2.410,模型组72.694±2.822,实验组与对照组比较无显著性差异(P>0.05),与模型组比较有极显著性差异(P<0.01)。
结论：通过8周、12周组织学观察、影像学评分、骨缺损修复面积以及骨缺损修复率结果,表明菟丝子多糖—HA复合物植入对兔股骨髁部松质骨缺损有明显的修复作用,其作用与BMP—HA—明胶复合物一致。
Objective:To observe the Cuscuta polysaccharide-hydroxyapatite complex partial implantation of the rabbit femoral condyle defect model of bone repair.
Method:The 48 rabbits with bilateral femoral condyle to cancellous bone defect model, resulting in femoral condyle diameter 6mm, after the model of 10mm deep, were randomly divided into 3 groups (experimental group/control group/model group):The experimental group implants partial defect of Cuscuta polysaccharide-HA complex; control group, partial defect in control group implanted BMP-HA-gelatin complex; Model group of local non-implant defect area of drug.8,12 weeks after X ray imaging score after bilateral femoral condyle from bone samples of bone defects in general observation, histological examination and repair of bone defect area and the rate of bone defect repair statistics, observation of 3 groups the difference between.
Result:
Postoperative imaging score:8 weeks after imaging for the experimental group, score 3.071±0.475, control group,3.143±0.363, model group,1.167±0.389, the experimental group compared with the control group no significant difference, P> 0.05, compared with the model group P<0.001; 12-week experimental group was 3.571±0.514, control group,3.714±0.469, model group,1.833±0.835, the experimental group compared with the control group no significant difference P> 0.05, compared with the model group P<0.001.
General observation:8 weeks, the experimental group, such as defects of soft tissue around the muscle slightly swollen, slightly white color, no congestion and edema, defect absorption implants can be seen clearly, and its soft texture obviously shows femoral condyle bone defect there is a large number of new bone callus growth to the Center from around the bone defect with new bone implants fuzzy boundaries; The control group, such as defects of soft tissue around the muscle with the experimental group cases, implants can be seen a small amount of absorption, but the experimental group than the high hardness and the edge of new bone defects less than the experimental group; Model group, such as defects of the muscles around the slight swelling of soft tissue, bone defect filling with red soft tissue, no significant bone growth.12 weeks, the experimental group, such as defects of soft tissue around the muscle swelling subsided, the color returned to normal, we can see a large number of defects generated callus and filling defects, color light than normal bone tissue, bone hardness of less than normal; The control group, such as defects of soft tissue around the muscle the situation with the experimental group, but bone less than the experimental group; Model group, such as defects of soft tissue around the muscle without swelling, without effusion, a small amount of surrounding bone to grow, it has hardened, we can see a larger soft tissue defect in the white area in which filling, and bone and soft tissue defect in the border area clear.
Area of bone defect repair:8 weeks to repair bone defect area of the experimental group 21.558±0.933, control group,21.749±0.992, model group,17.003±1.423. Experimental group, the control group compared with the model group has a very significant difference (P<0.001) the experimental group, control group, no significant difference, P> 0.05; 12-week experimental group,25.654±0.662, control group,25.734±0.681, model group,20.543±0.798. Experimental group compared with the control group no significant difference (P> 0.05), compared with the model group P<0.001, a very significant difference.
The rate of bone defect repair:8 weeks to repair bone defects in experimental group was 76.283±3.301, control group,76.961±3.509, model group,60.167±5.035. Experimental group compared with the control group no significant difference (P> 0.05), compared with the model group has a very significant difference (P<0.001); 12-week experimental group,90.777±2.341, control group,91.062±2.410, model group,72.694±2.822, Experimental group compared with the control group no significant difference (P> 0.05), compared with the model group has a very significant difference (P<0.001).
Conclusion:Through 8 weeks,12 weeks, histological observation and imaging score, bone defect area, as well as the results of bone defect repair rate that Cuscuta polysaccharide-HA complex implantation femoral condyle of rabbit cancellous bone defect repair of a clear role its role with the BMP-HA-gelatin complex line.
方法：将48只日本大耳白兔双侧股骨髁部进行松质骨缺损造模,造成股骨髁部直径6mm,深10mm的模型后,随机分为3组(实验组／对照组／模型组)：实验组缺损区局部植入菟丝子多糖-HA复合物；对照组缺损区局部植入BMP-HA-明胶复合物；模型组缺损区局部不植入药物。术后8、12周X摄片影像学评分后,取双侧股骨髁部松质骨骨缺损标本行大体观察、组织学观察并且对骨缺损修复面积和骨缺损修复率进行统计,比较3组之间差异。
结果：
术后影像学评分：8周时术后影像学评分为实验组3.071±0.475,对照组3.143±0.363,模型组1.167±0.389,实验组与对照组比较P>0.05,与模型组比较P<0.01；12周实验组3.571±0.514,对照组3.714±0.469,模型组1.833±0.835,实验组与对照组比较P>0.05,与模型组比较P<0.01。
大体观察：8周时,实验组缺损区周围肌肉等软组织轻微肿胀,颜色稍白,无充血水肿,缺损区植入物质地明显变软,明显吸收,股骨髁部骨缺损处有大量新生骨痂由周围向中心生长,骨缺损处新生骨痂与植入物边界模糊；对照组缺损区周围肌肉等软组织情况同实验组,可见植入物少量吸收,但硬度较实验组高,且缺损边缘新生骨痂量少于实验组；模型组缺损区周围肌肉等软组织轻微肿胀,骨缺损处有红色软组织充填,未见明显骨痂生长。12周时,实验组缺损区周围肌肉等软组织肿胀消退,颜色恢复正常,可见缺损区大量骨痂生成并充填,颜色较正常骨组织浅,硬度不及正常骨；对照组缺损区周围肌肉等软组织情况同上,但骨痂量较实验组少；模型组缺损区周围肌肉等软组织无肿胀,无渗出,周围有少量骨痂长出,但已硬化,较大缺损区内白色软组织充填于其中,骨痂与缺损区内软组织边界清楚。
骨缺损修复面积：8周时骨缺损修复面积为实验组21.558±0.933,对照组21.749±0.992,模型组17.003±1.423。实验组、对照组与模型组比较有极显著性差异(P<0.01),实验组与对照组比较无显著性差异(P>0.05)；12周实验组25.654±0.662,对照组25.734±0.681,模型组20.543±0.798。实验组与对照组比较无显著性差异(P>0.05),与模型组比较有极显著性差异(P<0.01)。
骨缺损修复率：8周时骨缺损修复率为实验组76.283±3.301,对照组76.961±3.509,模型组60.167±5.035。实验组与对照组比较无显著性差异(P>0.05),与模型组比较有极显著性差异(P<0.01)；12周时,实验组90.777±2.341,对照组91.062±2.410,模型组72.694±2.822,实验组与对照组比较无显著性差异(P>0.05),与模型组比较有极显著性差异(P<0.01)。
结论：通过8周、12周组织学观察、影像学评分、骨缺损修复面积以及骨缺损修复率结果,表明菟丝子多糖—HA复合物植入对兔股骨髁部松质骨缺损有明显的修复作用,其作用与BMP—HA—明胶复合物一致。
Objective:To observe the Cuscuta polysaccharide-hydroxyapatite complex partial implantation of the rabbit femoral condyle defect model of bone repair.
Method:The 48 rabbits with bilateral femoral condyle to cancellous bone defect model, resulting in femoral condyle diameter 6mm, after the model of 10mm deep, were randomly divided into 3 groups (experimental group/control group/model group):The experimental group implants partial defect of Cuscuta polysaccharide-HA complex; control group, partial defect in control group implanted BMP-HA-gelatin complex; Model group of local non-implant defect area of drug.8,12 weeks after X ray imaging score after bilateral femoral condyle from bone samples of bone defects in general observation, histological examination and repair of bone defect area and the rate of bone defect repair statistics, observation of 3 groups the difference between.
Result:
Postoperative imaging score:8 weeks after imaging for the experimental group, score 3.071±0.475, control group,3.143±0.363, model group,1.167±0.389, the experimental group compared with the control group no significant difference, P> 0.05, compared with the model group P<0.001; 12-week experimental group was 3.571±0.514, control group,3.714±0.469, model group,1.833±0.835, the experimental group compared with the control group no significant difference P> 0.05, compared with the model group P<0.001.
General observation:8 weeks, the experimental group, such as defects of soft tissue around the muscle slightly swollen, slightly white color, no congestion and edema, defect absorption implants can be seen clearly, and its soft texture obviously shows femoral condyle bone defect there is a large number of new bone callus growth to the Center from around the bone defect with new bone implants fuzzy boundaries; The control group, such as defects of soft tissue around the muscle with the experimental group cases, implants can be seen a small amount of absorption, but the experimental group than the high hardness and the edge of new bone defects less than the experimental group; Model group, such as defects of the muscles around the slight swelling of soft tissue, bone defect filling with red soft tissue, no significant bone growth.12 weeks, the experimental group, such as defects of soft tissue around the muscle swelling subsided, the color returned to normal, we can see a large number of defects generated callus and filling defects, color light than normal bone tissue, bone hardness of less than normal; The control group, such as defects of soft tissue around the muscle the situation with the experimental group, but bone less than the experimental group; Model group, such as defects of soft tissue around the muscle without swelling, without effusion, a small amount of surrounding bone to grow, it has hardened, we can see a larger soft tissue defect in the white area in which filling, and bone and soft tissue defect in the border area clear.
Area of bone defect repair:8 weeks to repair bone defect area of the experimental group 21.558±0.933, control group,21.749±0.992, model group,17.003±1.423. Experimental group, the control group compared with the model group has a very significant difference (P<0.001) the experimental group, control group, no significant difference, P> 0.05; 12-week experimental group,25.654±0.662, control group,25.734±0.681, model group,20.543±0.798. Experimental group compared with the control group no significant difference (P> 0.05), compared with the model group P<0.001, a very significant difference.
The rate of bone defect repair:8 weeks to repair bone defects in experimental group was 76.283±3.301, control group,76.961±3.509, model group,60.167±5.035. Experimental group compared with the control group no significant difference (P> 0.05), compared with the model group has a very significant difference (P<0.001); 12-week experimental group,90.777±2.341, control group,91.062±2.410, model group,72.694±2.822, Experimental group compared with the control group no significant difference (P> 0.05), compared with the model group has a very significant difference (P<0.001).
Conclusion:Through 8 weeks,12 weeks, histological observation and imaging score, bone defect area, as well as the results of bone defect repair rate that Cuscuta polysaccharide-HA complex implantation femoral condyle of rabbit cancellous bone defect repair of a clear role its role with the BMP-HA-gelatin complex line.
引文
[1]徐达传.实用临床骨缺损修复应用解剖学[M].北京,中国医药科技出版社,1999.10,1.
[2]李玉宝.骨修复纳米生物材料及其发展前景[J].中国国际新材料产业研讨会,生物医用材料专业论坛,2004,4-11.
[3]郑承泽,苏国礼等.羟基磷灰石明胶修复骨缺损的实验研究[J].广东医学,1995,16(9)：613-615.
[4]付志厚,王爱民.组织工程骨修复兔股骨髁骨缺损成骨效应的核素骨显像定量评价[J].中国组织工程研究与临床康复,2007,11(23)：4500-4503.
[5]周健,戴克戎,汤亭亭.BMSCs胶原刮膜对松质骨缺损的修复[J].上海第二医科大学学报,2004,24(8)：627-631.
[6]周健.复合骨髓干细胞生物陶瓷修复兔松质骨缺损的实验研究.上海第二医科大学博士学位论文,2003,4,1.
[7]Hollinger JO.Kleinschmidt JC.The critical size defect as an experimental model to test bone repair materials.[Journal Article] Journal of Craniofacial Surgery.1990,1(1):60-8.
[8]Thomas A,Einhorn,MD.Cliniically applied models of bone regeneration in tissue engineering research.Clinical orthopedics and related research,1999,367.59-67.
[9]肖建德.现代骨移植学[M].北京：科学出版社,2006,2：403.
[10]刘志强,周东风等.骨缺损修复的研究及进展.[J]广东牙病防治.2004,2(1)：4.
[11]徐达传.实用临床骨缺损修复应用解剖学[M].北京：中国医药科技出版社,1999,10：61-73.
[12]顾其胜,侯春林等.实用生物医用材料学[M].上海：上海科学技术出版社,2005：61.
[13]Concannon MJ,Boschert MT, Fitzpatrick L,et al.The use of demineralized bone powder in an onlay graft model[J].Plastic and Recon Surg,1995,95(6):1085.
[14]Mehlisch DR,Dallas A and Texos H.Collagen/hydroxylapatite implant for augmenting deficient alveolar ridges[J].Oral Surg,1989,68:505-508.
[15]Gongloff RK and Montgomery CK.Experimental study of the use of collagen tubes for implantation of particulate hydroxylapatite[J].J Oral Maxillofac Surg,1985,47:963-967.
[16]Ripamonti U,Schnitzler CM and Cleaton-Jones PC.Bone induction in a composite allogeneic bone/alloplastic implant[J].J ral Maxilllofac Surg,1989,47:963-967.
[17]郑承泽,苏国礼等.羟基磷灰石明胶修复骨缺损的实验研究[J].广东医学,1995,16(9)：613-615.
[18]徐建腔,胡蕴玉等.检测rhBMP-2／明胶复合材料的诱导成骨活性：修复兔长骨缺损的实验研究[J].中国临床康复,2002,6(2)：192-193.
[19]时述山主编.实用骨与软骨移植(第1版).北京：人民军医出版社,2002,133.
[20]Urist MR,Delange RJ,Finerman GA.Bone cell differentiation and growth factors[J].Science,1983,220(4598):680-686.
[21]Hcts QHerr GBone substitute with osteoinductive biomaterials surrect and clinical applications[J]. Int J Oral Maxillofac Surg,1994,23:413-420.
[22]赵廷宝,范清宇等.骨形成蛋白在骨缺损修复中的矛盾与克服[J].医学与哲 学.2000,21(8)：8.
[23]Groot KD.Carriers that concentrate native BMPs in vivo[J].Tissue Engineering, 1998,4:337-340.
[24]徐建强,胡蕴玉等.rhBMP2／明胶复合材料修复犬长骨节段性骨缺损的实验研究[J].创伤外科杂志,2002,4(4)：210-212.
[25]赵廷宝.复合生物活性材料修复骨缺损的研究进展[J].中国矫形外科杂志,2001,8(3)：270-274.
[26]Takaoka,K,Nakahara H,Yoshikawa H,et al.Ectopic bone induction on and in porous hydroxylapatite conbined with collagen and bone morphogenetic protein[J]. Clin Orthop,1998,234:250-254.
[27]王大章,费伟,刘松筠.高生物诱导活性复合人工骨整复骨缺损的实验研究[J].华西口腔医学杂志,1997,15(1)：3.
[28]Yan MN,Tang TT,Zhu ZA,et al.Effects of bone morphogenetic protein-2 gene therapy on the bone-implant interface:an experimental study with dogs. Zhonghua Yi Xue Za Zhi,2005,85:521-1525.
[29]Sachse A,Wagner A,Keller M,et al.Osteointegration of hydroxyapatite-titanium implants coated with nonglycosylated recombinant human bone morphogenetic protein-2 (BMP-2)in aged sheep.Bone,2005,37:699-710.
[30]Kusakabe,akamaki T,Nihei K,t al.Osseointegration of a hydroxyapatite-coated multilayered mesh stem.Biomaterials,2004,25:2957-2969.
[31]Kim HW,Lee EJ,Jun IK,et al.On the feasibility of phosphate glass and hydroxyapatite engineered coating on titanium.Biomed Mater Res A,2005,75:656- 667.
[32]Li LH,Kim HW,Lee SH,et al.Biocompatibility of titanium implants modified by microarc oxidation and hydroxyapatite coating.Biomed Mater Res A,2005,73: 48-54.
[33]Coathup MJ,Blackburn J,Goodship AE,et al.Role of hydroxyap-atite coating in resisting wear particle migration and osteolysis around acetabular omponents. Biom-aterials,2005,26:4161-4169.
[34]陈剑飞,林坚平,吴多能,等.异种骨基质明胶(BMG)的抗原性研究.中华创伤骨科杂志,2004,6：805—810.
[35]陈履平,倪正等.复方中药促骨生酊剂对骨折愈合影响的实验研究[J].中国骨伤,1998,11(4)：14-16.
[36]韦以宗总主编,现代中医骨科学(第1版).北京,中国中医药出版社,2004,52-53.
[37]杨金录.中医外敷内服治疗陈旧性骨折及骨缺损不连[J].现代康复,2001,5(3)：124.
[38]蓝旭,刘雪梅,葛宝丰等.中药接骨片对骨折愈合的影响[J].微循环杂志,2001,11(2)：38.
[39]史晓林,陈秀法,徐勤海.骨康注射液对骨折断端成骨生长因子及超微结构影响的实验研究[J].中国中医药科技,2005,12(1)：20-21.
[40]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[41]林燕萍,周瑞祥,王和鸣,冯尔宥.健骨颗粒对去卵巢骨质疏松模鼠血清TNF α、TGFβ1的影响[J].中国骨伤,2002,15(8)：465-467.
[42]李培英,王桂英,杜怀均等.中医补肾壮骨理论与微量元素[J].广东微量元素科学,1995,2(1)：52.
[43]刑国胜,谈志龙,王淑云,等.补肾健骨汤对成骨细胞增殖及碱性磷酸酶、骨钙素合成的影响.中草药,2001,32：1020—1022.
[44]沈霖,杜靖远,赵海波.补肾法对IL—1诱导的破骨细胞性骨吸收及破骨细胞MMP—9的影响.中医正骨,1999,11：3—5.
[45]任艳玲,郑洪新.中医药对TGF—β及其信号通路在骨重建中调控作用的研究.中医药学刊,2002,20：321—323.
[46]Hewison M,Zehnder D,Bland R,et al.Alpha-hydrocylase and the action of vitamin D[J].Mol Endovrinol,2002,25(2):141.
[47]潘振沧,戴鉴之.肾主骨理论研究进展[J].山东中医学院学报,1995,19(1)：63.
[48]赵玉堂,李金花,许灿.从骨钙含量与肾虚的关系探讨肾主骨的本质[J].前卫医药杂志,1994,11(2)：118.
[49]王建红,王敏章,欧阳栋,等.菟丝子黄酮对应激雌性大鼠下丘脑β-EP与腺垂体FSH、LH的影响[J].中药材,2002,25(12)：886-887
[50]蔡曦光,葛斌,许爱霞,等.菟丝子多糖对衰老小鼠脂质过氧化的影响.中国新药与临床杂志,2005,24(7)：521-523.
[51]卢建华,吴承亮,倪桂宝,王维佳,王靖,杨林,陈冰.红曲对去卵巢大鼠BMP2表达及成骨细胞增殖影响的实验研究[J].中国骨伤,2005,18(1)：25-27.
[52]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[53]任艳玲,郑洪新.中医药对TGF-β及其信号通路在骨重建中调控作用的研究[J].中医药学刊,2002,20(3)：321-323.
[54]魏玉玲,邹庆,傅刚等.中药增骨Ⅰ、Ⅱ号调节rhBMP-2对成纤维细胞的影响[J].中国骨质疏松杂志,2001,7(3)：250-252.
[55]王银喜,王金熙,徐智敏,等.局部植入接骨中药提取物促进骨愈合的实验研究[J].中国骨伤,2003,16(6)：346-348.
[56]林慧彬,林建强,林建群,等.山东4种菟丝子微量元素的比较研究.山东中医杂志,2002,21(2)：105.
[57]林慧彬,林建强,林建群,等.山东4种菟丝子氨基酸比较研究.时珍国医国药,001,12(3)：195.
[58]南京中医药大学.中药大辞典[M].上海：上海科学技术出版社,2006.3.1：2894—2897.
[59]金晓.菟丝子化学成分研究[J].中国中药杂志,1992；17(5)：292-293.
[60]Wang Z,Liu C,Fang J.H3,an acid polysaccharide from Cuscuta chinesis [J].J Chiness Pharm Sci,2001,10(2):57-59.
[61]Bao x,Wang Z,Fang J,et al.Structural features of an immunostimulating and antioxidant acidic polysaccharide from the seeds of Cuscuta chinensis[J].Planta Med, 2002,68(3):237-239.
[62]王展,鲍幸峰,方积年.菟丝子中两个中性杂多糖的化学结构研究[J].中草药,2001,32(8)：675-678.
[63]谢雁鸣,秦林林,于向东等.六种黄酮对成骨细胞体外培养作用的比较研究[J].中国中医基础医学杂志,2005,11,9：664-667.
[64]刘建辉,姜波,包永明等.菟丝子提取物在PC12细胞株中的神经营养样作用[J].生物化学与生物物理进展,2003,30(2)：226-227.
[65]孟凡迅等.神经细胞培养法观察单味中药促神经生长的研究[J].南通医学院学报,1999,19(1)：14-15.
[66]顾立刚,叶敏,阎玉凝等.菟丝子金丝桃苷体内外对小鼠免疫功能的影响[J].中国中医药信息杂志,2001,8(10)：42-44.
[67]熊跃斌,周楚华.淫羊霍及菟丝子醇提物对雄性生殖功能的影响[J].中国药学杂志,1994,29(2)：89-90.
[68]郭澄,邵元福,张纯.菟丝子生物学及其应用[M].成都：成都科技大学出版社,1996：66-69.
[69]张永祥主编.中药药理学新论,北京,人民卫生出版社.2004,510-571.
[70]郭圣荣主编.医药用生物降解性高分子材料(第1版).北京：化学工业出版社,2004：162.
[71]沈骅睿,吕文科,胡晓梅.菟丝子定向诱导成骨细胞向神经元细胞转化的研究[J].中华实用中西医杂志,2005,18(21)：1549-1551.
[72]谢雁明,秦林林等.骨碎补、淫羊霍、菟丝子总黄酮对成骨细胞体外培养影响的比较研究[J].中国中医药信息杂志,2005,12(7)：22-24.
[1]姜保国.创伤骨科手术学.北京：北京大学医学出版社,2004.
[2]Weiland AJ.Current concepts review:vascularized free bone transplants.J Bone Joint Surg Am,1981,63:166-169.
[3]Burchardt H,The biologyof bone graft repair.Clin Orthop Relat Res,1983,174: 28-42.
[4]Peter SJ,Miller ST,Zhu G, et al.In vivo degradation of a poly (propylene fumarate) /beta-tricalcium phosphate injectable composite scaffold.J Biomed Mater Res,1998, 41:1-7.
[5]麻松,阎景龙,林欣,潘海涛,王新涛,杨显生.微小颗粒骨移植诱导细胞生长治疗大鼠骨缺损[J].第四军医大学学报,2005,26(13)：1174-1176.
[6]杨朝晖,卢汉生.新鲜自体体松质骨微粒复合同种骨修复大段骨缺损实验研究[J].中国药物与临床,2006,6(1)：55-57.
[7]付振德,闫景龙,张晓颖,王慧婷.自体微小颗粒骨复合碱性成纤维细胞生长因子修复节段性骨缺损的实验研究[J].中国骨肿瘤骨病,2004,3(5)：299-305.
[8]张明,李世德,骨膜移植修复骨缺损的研究现状[J].实用骨科杂志,2004,10(1)：36-37.
[9]朱盛修,卢世壁,张伯勋等.有血液循环的骨膜移位术治疗骨不连接的临床研 究[J].中华实验外科杂志,1988,5(3)：137.
[10]梁雨田,张伯勋.家兔经皮自体骨髓移植在骨缺损瘢痕组织内成骨的X线表现[J].中国医学影像学杂志,1997,5(4)：224-227.
[11]Mark T,Scarborogy MD.Allograft-allograft healing?Salvage of massive allogrft after fracture[J].Clin Orthop Res,2001,328:28-33.
[12]Goldberg VM,Stevenson S.The biology of bone grafts.Semin Arthroplasty, 1993,4:58-63.
[13]Betz RR.Limitations of autograft and allograft:new synthetic solution. Orthope-dics,2002,25:s561-570.
[14]张志鹏,闫冰,闫景龙.复合同种异体颗粒骨修复兔桡骨缺损实验研究[J].中国康复理论与实践,200,11(6)：439-440.
[15]杨海平,王东,蔚晋斌,张登峰,武展雄.同种异体骨复合氨基胍对兔桡骨缺损愈合的影响[J].中国矫形外科杂志,2005,13(4)：282-285.
[16]Jingushi S,Urabe K,Okazaki K.Intramuscular bone induction by human recomb-inant bone morphogenetic protein-2 with beta-tricalcium phosphate as a carrier:in vivo bone banking for muscle-pedicle autograft. J-Orthop-Sci,2002,7(4):490-4.
[17]Cong Z,Jianxin W,Huaizhi F,et al.Repairing segmental bone defects with living porous ceramic cylinders:an experimental study in dog femora.J-Biomed-Mater-Res, 2001,55(1):28-32.
[18]McKee MD,Wild LM,Schemitsch EH,et al.The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects:early results of a prospective trial. J-Orthop-Trauma,2002,16(9):622-627.
[19]Lobenhoffer P,Gerich T,Witte F.Use of an injectable calcium phosphate bone cement in the treatment of tibial plateau fractures:a prospective study of twenty-six cases with twenty-month mean follow-up.J-Orthop-Trauma,2002,16(3):143-149.
[20]den-Boer FC,Bramer JA,Blokhuis TJ.Effect of recombinant human osteogenic protein-1 on the healing of a freshly closed diaphyseal fracture. Bone,2002, 31(1):158-164.
[21]Marukawa E,Asahina L,Oda M.Functional reconstruction of the non-human pri-mate mandible using recombinant human bone morphogenetic protein-2.Int J Oral Maxillofac Surg,2002,31(3):287-295.
[22]Nyman R,Mangnusson M,Sennerby L,et al.Membrane guided bone regeneration. Segmental radius defects studied in the rabbit.Acta Orthop Scand,1995,66:169.
[23]Asikainen AJ,Noponen J,Mesimaki K et al.Tyrosine derived polycarbonate me-mbrane is useful for guided bone regeneration in rabbit mandibular defects.J Mater Sci Mater Med,2005,16(8):753.
[24]Ueyama Y,Ishikawa K,Mano T.Usefulness as guided bone regeneration membr-ane of the alginate membrane.Biomaterials,2002,23(9):2027-2033.
[25]Eppley BL,Stal S,Hollier L,Kumar M.Compartmentalized bone regeneration of cranial defects with biodegradable barriers-effects of calcium sodium phosphate surface coatings on LactoSorb.J-Craniofac-Surg,2002,13(5):681-686.
[26]Cacciafesta V,Dalstra M,Bosch C.Growth hormone treatment promotes guided bone regeneration in rat calvarial defects.Eur-J-Orthod,2001,23(6):733-740.
[27]Takeishi H,Irie K,Okuda K.Molded bone augmentation by a combination of barrier membrane and recombinant human bone morphogenetic protein-2. Oral-Dis,2001,7(5):281-286.
[28]Giardino R,Aldini NN,Fini M.Enhanced guided bone regeneration with a resor-bable chamber containing demineralized bone matrix.J-Trauma,2002,52(5):933-937.
[29]Delloye C,Bone grafts using tissue engineering.Bull-Mem-Acad-R-Med-Belg, 2001,156(7-9):418-425.
[30]Hiroyuki Tsuchida,Junichi Hashimoto,Eric Crawford,et al.Engineered allog ene-ic mesenchymal stem cells repair femoral segmental defect in rats. Journal of Orthop-aedic Research,2003 (21):44-53.
[31]Ting-Ting Tang,Hua Lu,Ke-Rong Dai.Osteogenesis of freeze-dried cancellous bone allograft loaded with autologous marrow-derived mesenchymal cells.Materials Science and Engineering,2002,C 20:57-61.
[32]Oreffo RO,Triffitt JT.Future potentials for using osteogenic stem cells and biomaterials in orthopedics.Bone,1999,25:5-9.
[33]Rose FR,Oreffo RO.Bone tissue engineering:hope vs hype.Biochem Biophys Res Commun,2002,292:1-7.
[34]Langer R,Vacanti JP,Tissue engineering.Science,1993,260(5110):920-926.
[35]Bruder SP,Jaiswal N,Haynesworth SE.Growth kinetics,self-renewal,and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and follow cryopreservation.J Cell Biochem,1997,64:278-294.
[36]Guzzardella GA;Fini M;Torricelli P;Giavaresi G;Giardino R.Laser stimulation on bone defect healing:an in vitro study.Lasers-Med-Sci.2002,17(3):216-220.
[37]Cullinane DM,Fredrick A,Eisenberg SR.Induction of a neoarthrosis by precisely controlled motion in an experimental mid-femoral defect.J-Orthop-Res,2002, 20(3):579-586.
[38]江树连,丁锷,李保泉等.消瘀接骨散外敷对家兔骨折愈合的实验研究[J].中医外治杂志,2000,9(3)：6.
[39]蓝旭,刘雪梅,葛宝丰等.中药接骨片对骨折愈合的影响[J].微循环杂志,2001,11(2)：38.
[40]刘日光,沈冯君,杨述华,等.丹仙康骨胶囊对激素性股骨头缺血坏死血运变化的影响.中国中医骨伤科杂志,2001,9：15—17.
[41]史晓林,陈秀法,徐勤海.骨康注射液对骨折断端成骨生长因子及超微结构影响的实验研究[J].中国中医药科技,2005,12(1)：20-21.
[42]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[43]林燕萍,周瑞祥,王和鸣,冯尔宥.健骨颗粒对去卵巢骨质疏松模鼠血清TNFα、TGFβ1的影响[J].中国骨伤,2002,15(8)：465-467.
[44]李培英,王桂英,杜怀均等.中医补肾壮骨理论与微量元素[J].广东微量元素科学,1995,2(1)：52.
[45]卢建华,吴承亮,倪桂宝,王维佳,王靖,杨林,陈冰.红曲对去卵巢大鼠BMP2表达及成骨细胞增殖影响的实验研究[J].中国骨伤,2005,18(1)：25-27.
[46]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[47]任艳玲,郑洪新.中医药对TGF-β及其信号通路在骨重建中调控作用的研 究[J].中医药学刊,2002,20(3)：321-323.
[48]魏玉玲,邹庆,傅刚等.中药增骨Ⅰ、Ⅱ号调节rhBMP-2对成纤维细胞的影响[J].中国骨质疏松杂志,2001,7(3)：250-252.
[49]王银喜,王金熙,徐智敏,等.局部植入接骨中药提取物促进骨愈合的实验研究[J].中国骨伤,2003,16(6)：346-348.
[2]李玉宝.骨修复纳米生物材料及其发展前景[J].中国国际新材料产业研讨会,生物医用材料专业论坛,2004,4-11.
[3]郑承泽,苏国礼等.羟基磷灰石明胶修复骨缺损的实验研究[J].广东医学,1995,16(9)：613-615.
[4]付志厚,王爱民.组织工程骨修复兔股骨髁骨缺损成骨效应的核素骨显像定量评价[J].中国组织工程研究与临床康复,2007,11(23)：4500-4503.
[5]周健,戴克戎,汤亭亭.BMSCs胶原刮膜对松质骨缺损的修复[J].上海第二医科大学学报,2004,24(8)：627-631.
[6]周健.复合骨髓干细胞生物陶瓷修复兔松质骨缺损的实验研究.上海第二医科大学博士学位论文,2003,4,1.
[7]Hollinger JO.Kleinschmidt JC.The critical size defect as an experimental model to test bone repair materials.[Journal Article] Journal of Craniofacial Surgery.1990,1(1):60-8.
[8]Thomas A,Einhorn,MD.Cliniically applied models of bone regeneration in tissue engineering research.Clinical orthopedics and related research,1999,367.59-67.
[9]肖建德.现代骨移植学[M].北京：科学出版社,2006,2：403.
[10]刘志强,周东风等.骨缺损修复的研究及进展.[J]广东牙病防治.2004,2(1)：4.
[11]徐达传.实用临床骨缺损修复应用解剖学[M].北京：中国医药科技出版社,1999,10：61-73.
[12]顾其胜,侯春林等.实用生物医用材料学[M].上海：上海科学技术出版社,2005：61.
[13]Concannon MJ,Boschert MT, Fitzpatrick L,et al.The use of demineralized bone powder in an onlay graft model[J].Plastic and Recon Surg,1995,95(6):1085.
[14]Mehlisch DR,Dallas A and Texos H.Collagen/hydroxylapatite implant for augmenting deficient alveolar ridges[J].Oral Surg,1989,68:505-508.
[15]Gongloff RK and Montgomery CK.Experimental study of the use of collagen tubes for implantation of particulate hydroxylapatite[J].J Oral Maxillofac Surg,1985,47:963-967.
[16]Ripamonti U,Schnitzler CM and Cleaton-Jones PC.Bone induction in a composite allogeneic bone/alloplastic implant[J].J ral Maxilllofac Surg,1989,47:963-967.
[17]郑承泽,苏国礼等.羟基磷灰石明胶修复骨缺损的实验研究[J].广东医学,1995,16(9)：613-615.
[18]徐建腔,胡蕴玉等.检测rhBMP-2／明胶复合材料的诱导成骨活性：修复兔长骨缺损的实验研究[J].中国临床康复,2002,6(2)：192-193.
[19]时述山主编.实用骨与软骨移植(第1版).北京：人民军医出版社,2002,133.
[20]Urist MR,Delange RJ,Finerman GA.Bone cell differentiation and growth factors[J].Science,1983,220(4598):680-686.
[21]Hcts QHerr GBone substitute with osteoinductive biomaterials surrect and clinical applications[J]. Int J Oral Maxillofac Surg,1994,23:413-420.
[22]赵廷宝,范清宇等.骨形成蛋白在骨缺损修复中的矛盾与克服[J].医学与哲 学.2000,21(8)：8.
[23]Groot KD.Carriers that concentrate native BMPs in vivo[J].Tissue Engineering, 1998,4:337-340.
[24]徐建强,胡蕴玉等.rhBMP2／明胶复合材料修复犬长骨节段性骨缺损的实验研究[J].创伤外科杂志,2002,4(4)：210-212.
[25]赵廷宝.复合生物活性材料修复骨缺损的研究进展[J].中国矫形外科杂志,2001,8(3)：270-274.
[26]Takaoka,K,Nakahara H,Yoshikawa H,et al.Ectopic bone induction on and in porous hydroxylapatite conbined with collagen and bone morphogenetic protein[J]. Clin Orthop,1998,234:250-254.
[27]王大章,费伟,刘松筠.高生物诱导活性复合人工骨整复骨缺损的实验研究[J].华西口腔医学杂志,1997,15(1)：3.
[28]Yan MN,Tang TT,Zhu ZA,et al.Effects of bone morphogenetic protein-2 gene therapy on the bone-implant interface:an experimental study with dogs. Zhonghua Yi Xue Za Zhi,2005,85:521-1525.
[29]Sachse A,Wagner A,Keller M,et al.Osteointegration of hydroxyapatite-titanium implants coated with nonglycosylated recombinant human bone morphogenetic protein-2 (BMP-2)in aged sheep.Bone,2005,37:699-710.
[30]Kusakabe,akamaki T,Nihei K,t al.Osseointegration of a hydroxyapatite-coated multilayered mesh stem.Biomaterials,2004,25:2957-2969.
[31]Kim HW,Lee EJ,Jun IK,et al.On the feasibility of phosphate glass and hydroxyapatite engineered coating on titanium.Biomed Mater Res A,2005,75:656- 667.
[32]Li LH,Kim HW,Lee SH,et al.Biocompatibility of titanium implants modified by microarc oxidation and hydroxyapatite coating.Biomed Mater Res A,2005,73: 48-54.
[33]Coathup MJ,Blackburn J,Goodship AE,et al.Role of hydroxyap-atite coating in resisting wear particle migration and osteolysis around acetabular omponents. Biom-aterials,2005,26:4161-4169.
[34]陈剑飞,林坚平,吴多能,等.异种骨基质明胶(BMG)的抗原性研究.中华创伤骨科杂志,2004,6：805—810.
[35]陈履平,倪正等.复方中药促骨生酊剂对骨折愈合影响的实验研究[J].中国骨伤,1998,11(4)：14-16.
[36]韦以宗总主编,现代中医骨科学(第1版).北京,中国中医药出版社,2004,52-53.
[37]杨金录.中医外敷内服治疗陈旧性骨折及骨缺损不连[J].现代康复,2001,5(3)：124.
[38]蓝旭,刘雪梅,葛宝丰等.中药接骨片对骨折愈合的影响[J].微循环杂志,2001,11(2)：38.
[39]史晓林,陈秀法,徐勤海.骨康注射液对骨折断端成骨生长因子及超微结构影响的实验研究[J].中国中医药科技,2005,12(1)：20-21.
[40]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[41]林燕萍,周瑞祥,王和鸣,冯尔宥.健骨颗粒对去卵巢骨质疏松模鼠血清TNF α、TGFβ1的影响[J].中国骨伤,2002,15(8)：465-467.
[42]李培英,王桂英,杜怀均等.中医补肾壮骨理论与微量元素[J].广东微量元素科学,1995,2(1)：52.
[43]刑国胜,谈志龙,王淑云,等.补肾健骨汤对成骨细胞增殖及碱性磷酸酶、骨钙素合成的影响.中草药,2001,32：1020—1022.
[44]沈霖,杜靖远,赵海波.补肾法对IL—1诱导的破骨细胞性骨吸收及破骨细胞MMP—9的影响.中医正骨,1999,11：3—5.
[45]任艳玲,郑洪新.中医药对TGF—β及其信号通路在骨重建中调控作用的研究.中医药学刊,2002,20：321—323.
[46]Hewison M,Zehnder D,Bland R,et al.Alpha-hydrocylase and the action of vitamin D[J].Mol Endovrinol,2002,25(2):141.
[47]潘振沧,戴鉴之.肾主骨理论研究进展[J].山东中医学院学报,1995,19(1)：63.
[48]赵玉堂,李金花,许灿.从骨钙含量与肾虚的关系探讨肾主骨的本质[J].前卫医药杂志,1994,11(2)：118.
[49]王建红,王敏章,欧阳栋,等.菟丝子黄酮对应激雌性大鼠下丘脑β-EP与腺垂体FSH、LH的影响[J].中药材,2002,25(12)：886-887
[50]蔡曦光,葛斌,许爱霞,等.菟丝子多糖对衰老小鼠脂质过氧化的影响.中国新药与临床杂志,2005,24(7)：521-523.
[51]卢建华,吴承亮,倪桂宝,王维佳,王靖,杨林,陈冰.红曲对去卵巢大鼠BMP2表达及成骨细胞增殖影响的实验研究[J].中国骨伤,2005,18(1)：25-27.
[52]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[53]任艳玲,郑洪新.中医药对TGF-β及其信号通路在骨重建中调控作用的研究[J].中医药学刊,2002,20(3)：321-323.
[54]魏玉玲,邹庆,傅刚等.中药增骨Ⅰ、Ⅱ号调节rhBMP-2对成纤维细胞的影响[J].中国骨质疏松杂志,2001,7(3)：250-252.
[55]王银喜,王金熙,徐智敏,等.局部植入接骨中药提取物促进骨愈合的实验研究[J].中国骨伤,2003,16(6)：346-348.
[56]林慧彬,林建强,林建群,等.山东4种菟丝子微量元素的比较研究.山东中医杂志,2002,21(2)：105.
[57]林慧彬,林建强,林建群,等.山东4种菟丝子氨基酸比较研究.时珍国医国药,001,12(3)：195.
[58]南京中医药大学.中药大辞典[M].上海：上海科学技术出版社,2006.3.1：2894—2897.
[59]金晓.菟丝子化学成分研究[J].中国中药杂志,1992；17(5)：292-293.
[60]Wang Z,Liu C,Fang J.H3,an acid polysaccharide from Cuscuta chinesis [J].J Chiness Pharm Sci,2001,10(2):57-59.
[61]Bao x,Wang Z,Fang J,et al.Structural features of an immunostimulating and antioxidant acidic polysaccharide from the seeds of Cuscuta chinensis[J].Planta Med, 2002,68(3):237-239.
[62]王展,鲍幸峰,方积年.菟丝子中两个中性杂多糖的化学结构研究[J].中草药,2001,32(8)：675-678.
[63]谢雁鸣,秦林林,于向东等.六种黄酮对成骨细胞体外培养作用的比较研究[J].中国中医基础医学杂志,2005,11,9：664-667.
[64]刘建辉,姜波,包永明等.菟丝子提取物在PC12细胞株中的神经营养样作用[J].生物化学与生物物理进展,2003,30(2)：226-227.
[65]孟凡迅等.神经细胞培养法观察单味中药促神经生长的研究[J].南通医学院学报,1999,19(1)：14-15.
[66]顾立刚,叶敏,阎玉凝等.菟丝子金丝桃苷体内外对小鼠免疫功能的影响[J].中国中医药信息杂志,2001,8(10)：42-44.
[67]熊跃斌,周楚华.淫羊霍及菟丝子醇提物对雄性生殖功能的影响[J].中国药学杂志,1994,29(2)：89-90.
[68]郭澄,邵元福,张纯.菟丝子生物学及其应用[M].成都：成都科技大学出版社,1996：66-69.
[69]张永祥主编.中药药理学新论,北京,人民卫生出版社.2004,510-571.
[70]郭圣荣主编.医药用生物降解性高分子材料(第1版).北京：化学工业出版社,2004：162.
[71]沈骅睿,吕文科,胡晓梅.菟丝子定向诱导成骨细胞向神经元细胞转化的研究[J].中华实用中西医杂志,2005,18(21)：1549-1551.
[72]谢雁明,秦林林等.骨碎补、淫羊霍、菟丝子总黄酮对成骨细胞体外培养影响的比较研究[J].中国中医药信息杂志,2005,12(7)：22-24.
[1]姜保国.创伤骨科手术学.北京：北京大学医学出版社,2004.
[2]Weiland AJ.Current concepts review:vascularized free bone transplants.J Bone Joint Surg Am,1981,63:166-169.
[3]Burchardt H,The biologyof bone graft repair.Clin Orthop Relat Res,1983,174: 28-42.
[4]Peter SJ,Miller ST,Zhu G, et al.In vivo degradation of a poly (propylene fumarate) /beta-tricalcium phosphate injectable composite scaffold.J Biomed Mater Res,1998, 41:1-7.
[5]麻松,阎景龙,林欣,潘海涛,王新涛,杨显生.微小颗粒骨移植诱导细胞生长治疗大鼠骨缺损[J].第四军医大学学报,2005,26(13)：1174-1176.
[6]杨朝晖,卢汉生.新鲜自体体松质骨微粒复合同种骨修复大段骨缺损实验研究[J].中国药物与临床,2006,6(1)：55-57.
[7]付振德,闫景龙,张晓颖,王慧婷.自体微小颗粒骨复合碱性成纤维细胞生长因子修复节段性骨缺损的实验研究[J].中国骨肿瘤骨病,2004,3(5)：299-305.
[8]张明,李世德,骨膜移植修复骨缺损的研究现状[J].实用骨科杂志,2004,10(1)：36-37.
[9]朱盛修,卢世壁,张伯勋等.有血液循环的骨膜移位术治疗骨不连接的临床研 究[J].中华实验外科杂志,1988,5(3)：137.
[10]梁雨田,张伯勋.家兔经皮自体骨髓移植在骨缺损瘢痕组织内成骨的X线表现[J].中国医学影像学杂志,1997,5(4)：224-227.
[11]Mark T,Scarborogy MD.Allograft-allograft healing?Salvage of massive allogrft after fracture[J].Clin Orthop Res,2001,328:28-33.
[12]Goldberg VM,Stevenson S.The biology of bone grafts.Semin Arthroplasty, 1993,4:58-63.
[13]Betz RR.Limitations of autograft and allograft:new synthetic solution. Orthope-dics,2002,25:s561-570.
[14]张志鹏,闫冰,闫景龙.复合同种异体颗粒骨修复兔桡骨缺损实验研究[J].中国康复理论与实践,200,11(6)：439-440.
[15]杨海平,王东,蔚晋斌,张登峰,武展雄.同种异体骨复合氨基胍对兔桡骨缺损愈合的影响[J].中国矫形外科杂志,2005,13(4)：282-285.
[16]Jingushi S,Urabe K,Okazaki K.Intramuscular bone induction by human recomb-inant bone morphogenetic protein-2 with beta-tricalcium phosphate as a carrier:in vivo bone banking for muscle-pedicle autograft. J-Orthop-Sci,2002,7(4):490-4.
[17]Cong Z,Jianxin W,Huaizhi F,et al.Repairing segmental bone defects with living porous ceramic cylinders:an experimental study in dog femora.J-Biomed-Mater-Res, 2001,55(1):28-32.
[18]McKee MD,Wild LM,Schemitsch EH,et al.The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects:early results of a prospective trial. J-Orthop-Trauma,2002,16(9):622-627.
[19]Lobenhoffer P,Gerich T,Witte F.Use of an injectable calcium phosphate bone cement in the treatment of tibial plateau fractures:a prospective study of twenty-six cases with twenty-month mean follow-up.J-Orthop-Trauma,2002,16(3):143-149.
[20]den-Boer FC,Bramer JA,Blokhuis TJ.Effect of recombinant human osteogenic protein-1 on the healing of a freshly closed diaphyseal fracture. Bone,2002, 31(1):158-164.
[21]Marukawa E,Asahina L,Oda M.Functional reconstruction of the non-human pri-mate mandible using recombinant human bone morphogenetic protein-2.Int J Oral Maxillofac Surg,2002,31(3):287-295.
[22]Nyman R,Mangnusson M,Sennerby L,et al.Membrane guided bone regeneration. Segmental radius defects studied in the rabbit.Acta Orthop Scand,1995,66:169.
[23]Asikainen AJ,Noponen J,Mesimaki K et al.Tyrosine derived polycarbonate me-mbrane is useful for guided bone regeneration in rabbit mandibular defects.J Mater Sci Mater Med,2005,16(8):753.
[24]Ueyama Y,Ishikawa K,Mano T.Usefulness as guided bone regeneration membr-ane of the alginate membrane.Biomaterials,2002,23(9):2027-2033.
[25]Eppley BL,Stal S,Hollier L,Kumar M.Compartmentalized bone regeneration of cranial defects with biodegradable barriers-effects of calcium sodium phosphate surface coatings on LactoSorb.J-Craniofac-Surg,2002,13(5):681-686.
[26]Cacciafesta V,Dalstra M,Bosch C.Growth hormone treatment promotes guided bone regeneration in rat calvarial defects.Eur-J-Orthod,2001,23(6):733-740.
[27]Takeishi H,Irie K,Okuda K.Molded bone augmentation by a combination of barrier membrane and recombinant human bone morphogenetic protein-2. Oral-Dis,2001,7(5):281-286.
[28]Giardino R,Aldini NN,Fini M.Enhanced guided bone regeneration with a resor-bable chamber containing demineralized bone matrix.J-Trauma,2002,52(5):933-937.
[29]Delloye C,Bone grafts using tissue engineering.Bull-Mem-Acad-R-Med-Belg, 2001,156(7-9):418-425.
[30]Hiroyuki Tsuchida,Junichi Hashimoto,Eric Crawford,et al.Engineered allog ene-ic mesenchymal stem cells repair femoral segmental defect in rats. Journal of Orthop-aedic Research,2003 (21):44-53.
[31]Ting-Ting Tang,Hua Lu,Ke-Rong Dai.Osteogenesis of freeze-dried cancellous bone allograft loaded with autologous marrow-derived mesenchymal cells.Materials Science and Engineering,2002,C 20:57-61.
[32]Oreffo RO,Triffitt JT.Future potentials for using osteogenic stem cells and biomaterials in orthopedics.Bone,1999,25:5-9.
[33]Rose FR,Oreffo RO.Bone tissue engineering:hope vs hype.Biochem Biophys Res Commun,2002,292:1-7.
[34]Langer R,Vacanti JP,Tissue engineering.Science,1993,260(5110):920-926.
[35]Bruder SP,Jaiswal N,Haynesworth SE.Growth kinetics,self-renewal,and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and follow cryopreservation.J Cell Biochem,1997,64:278-294.
[36]Guzzardella GA;Fini M;Torricelli P;Giavaresi G;Giardino R.Laser stimulation on bone defect healing:an in vitro study.Lasers-Med-Sci.2002,17(3):216-220.
[37]Cullinane DM,Fredrick A,Eisenberg SR.Induction of a neoarthrosis by precisely controlled motion in an experimental mid-femoral defect.J-Orthop-Res,2002, 20(3):579-586.
[38]江树连,丁锷,李保泉等.消瘀接骨散外敷对家兔骨折愈合的实验研究[J].中医外治杂志,2000,9(3)：6.
[39]蓝旭,刘雪梅,葛宝丰等.中药接骨片对骨折愈合的影响[J].微循环杂志,2001,11(2)：38.
[40]刘日光,沈冯君,杨述华,等.丹仙康骨胶囊对激素性股骨头缺血坏死血运变化的影响.中国中医骨伤科杂志,2001,9：15—17.
[41]史晓林,陈秀法,徐勤海.骨康注射液对骨折断端成骨生长因子及超微结构影响的实验研究[J].中国中医药科技,2005,12(1)：20-21.
[42]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[43]林燕萍,周瑞祥,王和鸣,冯尔宥.健骨颗粒对去卵巢骨质疏松模鼠血清TNFα、TGFβ1的影响[J].中国骨伤,2002,15(8)：465-467.
[44]李培英,王桂英,杜怀均等.中医补肾壮骨理论与微量元素[J].广东微量元素科学,1995,2(1)：52.
[45]卢建华,吴承亮,倪桂宝,王维佳,王靖,杨林,陈冰.红曲对去卵巢大鼠BMP2表达及成骨细胞增殖影响的实验研究[J].中国骨伤,2005,18(1)：25-27.
[46]王华松,许申明.骨碎补对骨折愈合中TGF-β1表达的影响[J].中医正骨,2001,13(5)：6-8.
[47]任艳玲,郑洪新.中医药对TGF-β及其信号通路在骨重建中调控作用的研 究[J].中医药学刊,2002,20(3)：321-323.
[48]魏玉玲,邹庆,傅刚等.中药增骨Ⅰ、Ⅱ号调节rhBMP-2对成纤维细胞的影响[J].中国骨质疏松杂志,2001,7(3)：250-252.
[49]王银喜,王金熙,徐智敏,等.局部植入接骨中药提取物促进骨愈合的实验研究[J].中国骨伤,2003,16(6)：346-348.